A cyclized peptide derived from α fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1397-1404

  Torres, Cristian Gabriel ^a   Pino, Ana María ^a   Sierralta, Walter Daniel ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

fetoprotein; Canine mammary cancer cells; Cyclized peptide; Estradiol; HER2 neu

Indexed keywords

ALPHA FETOPROTEIN; CYCLOPEPTIDE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE A; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOG; DRUG SCREENING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CANCER STAGING; CELL PROLIFERATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ALPHA-FETOPROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DOGS; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM STAGING; PEPTIDES, CYCLIC; PHOSPHORYLATION; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 67649959808     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000367     Document Type: Article

References (32)

1. Russo IH and Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49-61, 1998.
2. Russo J, Lareef MH, Balogh G, Guo S and Russo IH: Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 87: 1-25, 2003.
3. Arpino G, Weichmann L, Osborne CK and Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233, 2008.
4. Shou J, Massrweh S, Osborne CK, Wakeling AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/ neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935, 2004.
5. Mesfin FB, Andersen TT, Jacobson HI, Zhu SJ and Bennett JA: Development of a synthetic cyclized peptide derived from alphafetoprotein that prevents the growth of human breast cancer. J Pept Res 58: 246-256, 2001.
6. DeFreest LA, Mesfin FB, Joseph L, McLeod DJ, Stallmer A, Reddy S, Balulad SS, Jacobson HI, Andersen TT and Bennett JA: Synthethic peptide derived from alpha-fetoprotein that inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization. J Pept Res 63: 409-419, 2004.
7. Bennett JA, DeFreest L, Anaka I, Saadati H, Balulad S, Jacobson HI and Andersen TT: AFPep: an anti-breast cancer peptide that is orally active. Breast Cancer Res Treat 98: 133-141, 2006.
8. Parikh RR, Gildener-Leapman N, Narandran A, Lin H-Y, Lemanski N, Bennett JA, Jacobson HJ and Andersen TT: Prevention of N-Methyl-N-Nitrosourea-induced breast cancer by α-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP. Clin Cancer Res 11: 8512-8520, 2005.
9. Torres C, Antileo E, Epuñan MJ, Pino AM, Valladares LE and Sierralta WD: A cyclic peptide derived from alpha fetoprotein inhibits the proliferative effects of EGF and estradiol in MCF7 cells. Oncol Rep 19: 1597-1604, 2008.
10. Sierralta WD, Epuñan MJ, Reyes JM, Valladares LE, Andersen TT, Bennett JA, Jacobson HI and Pino AM: A peptide derived from alpha-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture. Oncol Rep 19: 229-235, 2008.
11. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G and Bocchini V: Cancer incidence in pet dogs: findings of the animal tumor registry of Genoa, Italy. J Vet Intern Med 22: 976-984, 2008.
12. Flores E and Cattaneo G: Tumores mamarios en caninos domésticos. Epidemiología, criterios de diagnóstico y enfoque terapéutico. (Epidemiology, diagnosis and therapy of mammary tumors in pet dogs). Monogr Med Vet (Chile) 21: 67-78, 2001.
13. Misdorp W: Canine mammary tumours: protective effect of late ovariectomy and stimulating effects of progestins. Vet Q 10: 26-33, 1988.
14. Queiroga FL, Pérez-Alenza MD, Silvan G, Peña L, Lopes C and Illera JC: Role of steroid hormones and prolactin in canine mammary cancer. J Steroid Biochem Mol Biol 94: 181-187, 2005.
15. Tashbaeva RE, Hwang DN, Song GS, Choi NH, Lee JH, Lyoo YS, Lee SJ, Jung DI, Kim HY and Sur JH: Cellular characterization of multidrug resistance P-glycoprotein, alpha fetoprotein, and neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver. Vet Pathol 44: 600-606, 2007.
16. Misdorp W: Tumors of the mammary gland. In: Tumors in Domestic Animals. Meuten D (ed). Blackwell, Iowa, pp575-606, 2002.
17. Pagnini U, Florio S, Crispino L, Pagnini G, Colangelo D, Rocco D, Pacilio C, Pacilio M, Macaluso M and Giordano A: Direct effect of a gonadotropin-releasing hormone agonist on the growth of canine mammary tumour cells. J Cell Biochem 85: 470-481, 2002.
18. Simon D, Knebel JW, Baumgartner W, Auf der Heide M, Meyer-Linderberg A and Nolte I: In vitro efficacy of chemotherapeutics by 50% inhibitory concentrations in cell culture of mammary gland tumors obtained from dogs. Am J Vet Res 62: 1825-1830, 2001.
19. Sartin E, Barnes S, Toivio-Kinnucan M, Wright JC and Wolfe LG: Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and senstivity to tamoxifen and doxorubicin. Anticancer Res 13: 229-236, 1993.
20. Bennett JA, Mesfin FB, Andersen TT, Gierthy JF and Jacobson HI: A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc Natl Acad Sci USA 99: 2211-2215, 2002.
21. Andersen TT, Georgekutty J, Defreest LA, Amaratunga G, Narendran A, Lemanski N, Jacobson HI and Bennett JA: An alpha-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen. Br J Cancer 97: 327-333, 2007.
22. Simoncini T and Genazzani AR: Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148: 281-292, 2003.
23. Kelly MJ and Levin ER: Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12: 152-156, 2001.
24. Cunliffe HE, Ringnér M, Bilke S, Walker RL, Cheung JM, Chen Y and Meltzer PS: The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res 63: 7158-7166, 2003.
25. Yu D and Hung MC: Role of erbB2 in breast cancer chemosensitivity. Bioessays 22: 673-680, 2000.
26. Razandi M, Pedram A, Park ST and Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278: 2701-2712, 2003.
27. Nilsson UW, Garvin S and Dabrosin C: MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102: 253-261, 2007.
28. Fox EM, Andrade J and Shupnik MA: Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids (In press).
29. Song RXD, Zhang Zh, Chen Y, Bao Y and Santen RJ: Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF7 breast cancer cells. Endocrinology 148: 4091-4101, 2007.
30. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
31. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ and Podratz KC: Activity of lapatinib, a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 98: 1076-1084, 2008.
32. Bose R and Zhang X: The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp Cell Res (In press).